Cognitive problems in patients on androgen deprivation therapy: a qualitative pilot study
- PMID: 22975107
- PMCID: PMC3720684
- DOI: 10.1016/j.urolonc.2012.07.003
Cognitive problems in patients on androgen deprivation therapy: a qualitative pilot study
Abstract
Objectives: Androgen deprivation therapy (ADT; also known as hormone therapy) is a well-established treatment for prostate cancer patients with rising prostate-specific antigen levels after localized treatment, and for those with metastatic disease. The neurological impact of ADT has been likened to that of aging and is therefore theorized to impair cognitive functioning in prostate cancer patients. We briefly summarize the research that has examined cognitive functioning of ADT patients primarily through neuropsychological assessment. A qualitative pilot study is presented with the aim of describing ADT patients' experiences of cognitive changes since starting ADT.
Materials and methods: Semistructured telephone interviews were undertaken with 11 community-dwelling prostate cancer patients undergoing ADT following definitive localized treatment. Participants were recruited via online prostate cancer support forums. Content analyses were conducted to establish relevant themes, which in this case were the cognitive domains of impairment.
Results: Eight of the 11 participants reported impairments in the domains of concentration, information processing, verbal fluency, visual information processing/visuospatial function, memory, and executive dysfunction. Neurobehavioral problems, including neurofatigue and apathy were also reported.
Conclusions: The interviews illustrate the potential negative effects of ADT on cognitive and neurobehavioral functions, and their impact on patients' work and in their daily lives. We describe how the field of cognitive rehabilitation offers promising tools to assist ADT patients with cognitive problems.
Keywords: Androgen deprivation therapy; Cognitive function; Neurobehavioral function; Neuropsychology; Oncology; Prostate cancer; Rehabilitation.
Copyright © 2013 Elsevier Inc. All rights reserved.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Cognitive and neurobehavioral symptoms in patients with non-metastatic prostate cancer treated with androgen deprivation therapy or observation: A mixed methods study.Soc Sci Med. 2016 May;156:80-9. doi: 10.1016/j.socscimed.2016.03.016. Epub 2016 Mar 17. Soc Sci Med. 2016. PMID: 27019142 Free PMC article.
-
The impact of long-term androgen deprivation therapy on cognitive function and socioeconomic decision making in prostate cancer patients.Psychooncology. 2020 Aug;29(8):1338-1346. doi: 10.1002/pon.5442. Epub 2020 Jul 2. Psychooncology. 2020. PMID: 32539186
-
Computerized cognitive training in prostate cancer patients on androgen deprivation therapy: a pilot study.Support Care Cancer. 2018 Jun;26(6):1917-1926. doi: 10.1007/s00520-017-4026-8. Epub 2017 Dec 27. Support Care Cancer. 2018. PMID: 29282534 Free PMC article. Clinical Trial.
-
Cognitive effects of hormone therapy in men with prostate cancer: a review.Cancer. 2008 Sep 1;113(5):1097-106. doi: 10.1002/cncr.23658. Cancer. 2008. PMID: 18666210 Free PMC article. Review.
-
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.Cochrane Database Syst Rev. 2020 Dec 12;12(12):CD013245. doi: 10.1002/14651858.CD013245.pub2. Cochrane Database Syst Rev. 2020. PMID: 33314020 Free PMC article.
Cited by
-
Cancer-related cognitive impairment in older adults with acute myeloid leukemia treated with hypomethylating agents and venetoclax chemotherapy: a longitudinal descriptive study.Support Care Cancer. 2024 Jul 3;32(7):485. doi: 10.1007/s00520-024-08673-2. Support Care Cancer. 2024. PMID: 38960966 Free PMC article.
-
Risk of cognitive impairment in men with advanced prostate cancer treated with NHAs: A systematic review and network meta-analysis.Clin Transl Sci. 2023 Feb;16(2):313-325. doi: 10.1111/cts.13451. Epub 2022 Nov 20. Clin Transl Sci. 2023. PMID: 36369801 Free PMC article.
-
[Urogeriatric thinking using the example of antiandrogen therapy for prostate cancer].Urologie. 2024 Sep;63(9):867-877. doi: 10.1007/s00120-024-02397-1. Epub 2024 Aug 7. Urologie. 2024. PMID: 39110185 German.
-
Inequities in Definitive Treatment for Localized Prostate Cancer Among Those With Clinically Significant Mental Health Disorders.Urol Pract. 2023 Nov;10(6):656-663. doi: 10.1097/UPJ.0000000000000457. Epub 2023 Sep 26. Urol Pract. 2023. PMID: 37754206 Free PMC article.
-
UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies.Can Urol Assoc J. 2022 Aug;16(8):E416-E431. doi: 10.5489/cuaj.8054. Can Urol Assoc J. 2022. PMID: 35905482 Free PMC article. No abstract available.
References
-
- Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238–44. - PubMed
-
- Janowsky JS. The role of androgens in cognition and brain aging in men. Neuroscience. 2006;138:1015–20. - PubMed
-
- Davidson JM, Chen JJ, Crapo L, et al. Hormonal changes and sexual function in aging men. J Clin Endocrinol Metab. 1983;57:71–7. - PubMed
-
- Vermeulen A. Clinical review 24: Androgens in the aging male. J Clin Endocrinol Metab. 1991;73:221–4. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical